Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Congenital Adrenal Hyperplasia Clinical Trials

A listing of Congenital Adrenal Hyperplasia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (4) clinical trials

Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia

CAH patients are treated with glucocorticoids and mineralocorticoids. Ideally, the glucocorticoid doses should be sufficient to suppress the elevated ACTH secretion, and hence attenuate the increase in androgen levels. Because of this, CAH patients use higher steroid doses than patients with autoimmune adrenal insufficiency (Addison's disease) and therefore are in ...

Phase

Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia

This is a 6-week, multiple-dose, dose escalation study of SPR001 for the treatment of adults with classic CAH. After screening, eligible patients will be enrolled into a 6-week treatment period followed by a 4-week washout/safety follow-up period. It is initially planned that up to approximately 18 patients in 2 dose ...

Phase

Safety Tolerability Pharmacokinetics and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

This is a Phase 2, open-label, multiple-dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 in approximately 16 to 20 adult female and male subjects (18 to 50 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). ...

Phase

Nevanimibe HCl for the Treatment of Classic CAH

This is a multicenter, intra-subject dose-titration open-label study of nevanimibe hydrochloride (HCl) for the treatment of classic congenital adrenal hyperplasia (CAH). Following a Screening Period of approximately 2-14 weeks, eligible subjects will enter a Baseline Period of approximately 2-8 weeks and then a 12-week Treatment Period. It is anticipated that ...

Phase